Evommune (EVMN) Operating Income (2024 - 2026)

Evommune (EVMN) has 3 years of Operating Income data on file, last reported at -$24.0 million in Q1 2026.

• Quarterly Operating Income fell 59.35% year-over-year to -$24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.0 million (changed N/A YoY) and the FY2025 annual result came in at -$81.1 million, down 15.79% from the prior year.
• Operating Income improved to -$24.0 million in Q1 2026 per EVMN's latest filing, from -$29.7 million in the prior quarter.
• Across five years, Operating Income topped out at -$13.3 million in Q3 2025 and bottomed at -$29.7 million in Q4 2025.
• The 3-year median for Operating Income is -$19.0 million (2024), against an average of -$20.0 million.
• The widest annual swing landed in 2025, when Operating Income gained 19.31%; it then slumped 59.35% in 2026.
• Tracing EVMN's Operating Income over 3 years: stood at -$21.5 million in 2024, then sank by 38.51% to -$29.7 million in 2025, then increased by 19.39% to -$24.0 million in 2026.
• Per Business Quant, the three latest EVMN Operating Income figures stand at -$24.0 million (Q1 2026), -$29.7 million (Q4 2025), and -$13.3 million (Q3 2025).

Peer Comparison